BiotechTube

GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

High-risk Myelodysplastic Syndromes

Conditions

High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Systemic Mastocytosis, Mast Cell Leukemia

Trial Timeline

Jan 1, 2020 → Sep 29, 2021

NCT ID
NCT03214666

About GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II

GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II is a phase 1/2 stage product being developed by GT Biopharma for High-risk Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT03214666. Target conditions include High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Systemic Mastocytosis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03214666Phase 1/2Terminated

Competing Products

13 competing products in High-risk Myelodysplastic Syndromes

See all competitors
ProductCompanyStageHype Score
SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3
77
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
77
Pembrolizumab + BCGMerckPhase 3
77
Blinatumomab + Investigator's Choice Chemotherapy + DexamethasoneAmgenPhase 2
51
BlinatumomabAmgenPhase 2
51
Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + PrednisoneGilead SciencesPhase 3
76
Darolutamide + ADTBayerPhase 2
49
EsmololBaxterPhase 3
74
N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells)ImmunityBioPhase 2
49
N-803 + ETBX-071 + M-CENKImmunityBioPhase 2
49
Cretostimogene GrenadenorepvecCG OncologyPhase 2
49
RP2 InjectionReplimunePhase 2
44
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7PDS BiotechnologyPhase 1
25